CD8-positive tumor-infiltrating lymphocytes (TILs), which are representative markers of the tumor microenvironment (TME), also serve as predictors of anti-programmed cell death-1 (PD-1) treatment in NSCLC (19). The gene discussed is CD8A; the disease is neoplasm.